Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2019-04-03 Director's Dealing
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2019-04-03 English
PRIMARY DOCUMENT
Director's Dealing
2019-03-28 English
FORM 6-K
Regulatory Filings
2019-03-27 English
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
Regulatory Filings Classification · 95% confidence The document is a press release dated March 27, 2019, announcing that Novartis received FDA approval for Mayzent® (siponimod) to treat secondary progressive multiple sclerosis (SPMS). This type of announcement, detailing a significant regulatory event (FDA approval) and providing key clinical data summaries and future outlook, is characteristic of an Earnings Release (ER) or a general press release related to business operations/product milestones. Since it is not a full quarterly/annual report (10-K or IR), nor a transcript (CT), nor a specific management discussion (MDA), and it focuses on the immediate release of positive news regarding a product approval, the most fitting category among the provided options is Earnings Release (ER), as these often include major operational news alongside financial reporting, or it could be classified as Regulatory Filing (RNS) if it were purely a mandatory filing. Given the structure as a formal press release announcing a major product milestone and regulatory success, ER is often used for such high-impact news releases, although RNS is a strong fallback. However, since this is a specific product/regulatory announcement rather than a general regulatory filing, and it contains substantial detail about the approval and trial data, it functions similarly to an ER announcing a major positive event. Given the options, and recognizing this is a major corporate announcement, I will lean towards ER as it communicates key performance/product news, but RNS is also plausible. Since it is not explicitly tied to a quarterly earnings period but rather a specific FDA action, RNS (Regulatory Filings/General Announcement) is the safest fit for a non-standard, non-financial-period-specific corporate announcement that isn't covered by other specific codes like M&A or Capital Change.
2019-03-27 English
FORM 6-K
Regulatory Filings
2019-03-22 English
PRIMARY DOCUMENT
Director's Dealing
2019-03-15 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.